New York State Teachers Retirement System Sells 300 Shares of The Carlyle Group Inc. (NASDAQ:CG)
New York State Teachers Retirement System trimmed its position in The Carlyle Group Inc. (NASDAQ:CG – Free Report) by 0.7% during the 4th quarter, HoldingsChannel reports. The firm owned 44,246 shares ...
The Search For 7% Investment Grade Yields, Part 2: Carlyle And Its Baby Bond
The Carlyle Group offers solid investment-grade debt with consistent dividends. Learn why CG stock’s baby bond, CGABL, is a ...
Carlyle price target lowered to $47 from $50 at BofA
BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform ...
Carlyle's profit misses estimates as private equity business weighs
Carlyle Group's distributable fourth-quarter earnings missed market expectations on Tuesday, eclipsing a strong growth in the ...
BioPharma Dive1d
Bluebird, at risk of default, agrees to take-private deal
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
Carlyle’s slower fee growth draws questions as private-equity firm’s stock falls
Carlyle Group Inc.’s stock fell 5% on Tuesday after the private-equity firm signaled a slowdown in its fee-related earnings ...
Carlyle's Savino Expects IPOs to Increase in 2025
Matt Savino, Carlyle global head of capital markets, expects the IPO market to improve in 2025. He is on "Bloomberg ." ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...